Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Emergent BioSolutions Inc. incurred term loan of $150 million with OrbiMed Royalty & Credit Opportunities V, LP at Term SOFR (subject to a floor of 3.00%) plus 6.25% per annum maturing April 16, 2031.
- Instrument
- term loan
- Principal
- $150 million
- Counterparty
- OrbiMed Royalty & Credit Opportunities V, LP
- Rate
- Term SOFR (subject to a floor of 3.00%) plus 6.25% per annum
- Maturity
- April 16, 2031
- Event
- incurrence
Exact text from the filing
The Term Loan Agreement provides for (i) a term loan (the “Initial Term Loan”) in an aggregate principal amount equal to $150 million, which was drawn in full on the date of entry into the Term Loan Agreement (the “Closing Date”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
Emergent BioSolutions Inc. entered into Term Loan Agreement with OrbiMed Royalty & Credit Opportunities V, LP valued at $150 million (effective 2026-04-16).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- OrbiMed Royalty & Credit Opportunities V, LP
- Value
- $150 million
- Effective
- 2026-04-16
Exact text from the filing
On April 16, 2026, Emergent BioSolutions Inc. (the “Company”) entered into a Credit Agreement (the “Term Loan Agreement”) by and among the Company, the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Emergent BioSolutions Inc. terminated Prior Credit Agreement with OHA Agency LLC.
- Action
- termination
- Agreement
- credit facility
- Counterparty
- OHA Agency LLC
Exact text from the filing
repay all amounts outstanding and terminate commitments under the Credit Agreement dated as of August 30, 2024, by and among the Company, the lenders from time to time party thereto and OHA Agency LLC as administrative agent (as amended, the "Prior Credit Agreement")
View on SEC.gov